

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Duality Biotherapeutics, Inc.**

**映恩生物**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock code: 9606)**

### **VOLUNTARY ANNOUNCEMENT**

## **KEY PRODUCT DB-1310 GRANTED U.S. FDA FAST TRACK DESIGNATION**

This announcement is made by Duality Biotherapeutics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on the voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that our key product DB-1310, an antibody-drug conjugate (“**ADC**”) targeting human epidermal growth factor receptor 3 (HER3), has been granted a Fast Track Designation by the U.S. Food and Drug Administration (“**FDA**”) for the treatment of adult patients with advanced, unresectable or metastatic non-squamous non-small cell lung (nsqNSCLC) cancer with an epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutation with disease progression on or after treatment with a third generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.

### **ABOUT FAST TRACK DESIGNATION**

The FDA Fast Track Designation is an approach to expedite development and review of potential medicines. A drug which is granted Fast Track Designation is intended to treat a serious condition and address unmet medical need, and may be the first therapy for a specific condition, or offer clinically significant advantages over available therapies, or benefit patients who are unresponsive to or intolerant of available therapies.

### **ABOUT DB-1310**

DB-1310 is a novel ADC targeting HER3 developed using the Company’s proprietary DITAC platform. In June 2025, Dr. Aaron E. Lisberg from the University of California, Los Angeles (UCLA) presented first-in-human Phase I/IIa clinical trial data (NCT05785741) for DB-1310 in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The results demonstrated encouraging efficacy and a manageable safety in patients with advanced solid tumors who had failed standard therapies.

### **ABOUT THE COMPANY**

Duality Biotherapeutics is a key player in the global ADC landscape, dedicated to the development of innovative therapeutics in this fast-growing drug modality to treat cancer, autoimmune diseases, and beyond.

## **RISK WARNING**

**DB-1310 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.**

By order of the Board  
**Duality Biotherapeutics, Inc.**  
**Dr. ZHU Zhongyuan**  
*Chairman of the Board, Executive  
Director and Chief Executive Officer*

Hong Kong, July 22, 2025

*As at the date of this announcement, the board of directors of the Company comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Ms. SI Wen as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.*